Ascent Biomedical Ventures

Peerbridge Health Inc. is a digital health company specializing in advanced remote monitoring solutions for vital signs. The company develops a wireless electrocardiogram (ECG) monitor, Peerbridge Cor, which provides real-time heart data to physicians and allows for continuous arrhythmia detection over seven days. In addition to Peerbridge Cor, the company offers products like Peerbridge CorHRV and Peerbridge Cor+, which monitor a range of vital signs including heart rate rhythm, respiratory rate, temperature, oxygen saturation, and heart rate variability. Founded in 2012 in New York by Angelo Acquista, Peerbridge Health holds two pioneering patents for medical-grade monitoring of vital signs, with additional patents pending. By enhancing the accuracy and affordability of diagnoses, Peerbridge Health aims to improve patient outcomes and support various medical, wellness, and performance-based monitoring needs.

Motus GI Holdings, Inc. is a medical technology company based in Fort Lauderdale, Florida, with operations in the United States and Israel. The company specializes in developing endoscopy solutions aimed at improving clinical outcomes and reducing costs associated with gastrointestinal conditions. Its primary product, the Pure-Vu System, is designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures, thereby enhancing the overall patient experience and aiding in the early detection of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and holds CE marking for use in the European Economic Area.

eCaring offers a web-based home care monitoring and management system designed to enhance communication between care managers, providers, and family members. The platform enables home health aides, patients, and family members to document vital health information, including physical and mental states, medication adherence, and other significant behaviors in real-time. This data collection allows healthcare providers to identify issues and respond promptly, thereby preventing hospital readmissions and improving overall patient outcomes. eCaring consists of several interrelated products, including CareTracker, which facilitates the entry of detailed health information, CareJournal, which provides a comprehensive view of patient data, and CarePortrait, which offers insights into clinically significant trends over time. Additionally, CareAlerts, currently in development, will notify users of critical health changes via email and SMS. By streamlining home healthcare management, eCaring aims to increase care coordination, enhance provider productivity, and reduce stress for patients and their families.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Targanox is a biopharmaceutical company focused on developing therapeutic drugs aimed at treating oncology and metabolic-related illnesses. The company's innovative approach targets oxidative stress, a biochemical condition associated with various diseases, by specifically addressing oxidized cystine residues of crucial proteins involved in human health. Targanox's drugs are designed to prevent stress-induced diseases, providing patients with advanced treatment options that enhance recovery and improve health outcomes. Through its research and development efforts, Targanox aims to address significant medical needs and contribute to the advancement of personalized medicine.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Ouroboros, Inc. is a San Diego-based company that specializes in the manufacturing of spine products designed to address degenerated disc disease. The company focuses on developing innovative solutions to improve patient outcomes in spinal health, leveraging advanced technologies and research in the field of orthopedics. Through its commitment to quality and efficacy, Ouroboros aims to provide healthcare professionals with reliable tools to enhance the treatment of spinal conditions.

InnerPulse, Inc. develops technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias. It offers invasive treatment that enables physicians to implant the life-saving Percutaneous Implantable Cardioverter Defibrillator within the patient's vascular system. InnerPulse, Inc. was formerly known as Interventional Rhythm Management, Inc.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Aryx Therapeutics is a biopharmaceutical company that specializes in the development of innovative oral therapies aimed at chronic diseases. The company leverages its expertise in retrometabolic drug design to create product candidates that address and eliminate safety concerns associated with existing, commercially successful medications. By focusing on improving the safety profiles of these therapies, Aryx Therapeutics seeks to enhance patient outcomes and provide better treatment options in the pharmaceutical market. The company's commitment to advancing drug safety is supported by a strong portfolio of intellectual property.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, founded in 2003. The company specializes in the design and development of non-fusion motion preservation systems for treating degenerative diseases of the cervical and lumbar spine. Its flagship products, the M6-C and M6-L artificial discs, offer innovative options for artificial cervical and lumbar disc replacements, respectively. These discs are uniquely engineered to replicate the anatomical and biomechanical properties of natural intervertebral discs by incorporating an artificial nucleus and annulus. Spinal Kinetics collaborates with spine surgeons to enhance the effectiveness of its devices, which are distributed in various countries, including Australia, Germany, Spain, and the United Kingdom. The company operates as a subsidiary of Orthofix Medical Inc.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Entigo is a company that develops enterprise warranty chain management solutions, aimed at streamlining warranty processing for businesses. Its flagship product, Entigo Warranty, facilitates the administration of warranty claims and registrations, while Entigo Catalyst assists in evaluating and enhancing current warranty processes. The company offers a range of services, including project management, implementation consulting, and systems integration, which help automate claims processing, reduce errors, and improve overall efficiency. Entigo's solutions also incorporate analytics and reporting capabilities, enabling clients to make data-driven decisions that enhance product quality and minimize warranty costs. Serving a diverse clientele that includes Fortune 500 manufacturers in sectors such as automotive, aerospace, and industrial equipment, Entigo is committed to simplifying warranty processes and fostering collaboration among warranty chain partners. Founded in 1995, the company is headquartered in Exton, Pennsylvania.